Please login to the form below
Deal Watch table for August 2014
Table listing all the major pharma mergers, acquisitions and collaborations in the past month
This table lists all the major pharma collaborations, acquisitions and mergers agreed during August 2014.
For an indepth analysis of these deals, read 'Pharma deals during August 2014'
| Licensor acquired / licensee acquirer | Deal type | Product / technology | Headline ($m) |
| InterMune/ Roche | Company acquisition | Pirfenidone for idiopathic pulmonary fibrosis (IPF) (approved EU, Canada) | 8,300 |
| MannKind/ Sanofi | Licence | Afrezza (human insulin) Rapid-Acting Inhaled Insulin (approved US) | 925 |
| Charleston Laboratories/ Daiichi Sankyo* | Collaboration (co-promotion rights) | Hydrocodone combination products, inc CL-108, for acute pain and reduction of Opioid-Induced Nausea and Vomiting (OINV) (phase III) | 650 |
| Gamida Cell/ Novartis | Investment, option to acquire | Stem cell therapies including NiCord (phase I/II) | 635 |
| Beijing Jialin Pharma/ Luye Pharma | Company acquisition (58%) | CV and cancer drug portfolio | 600 |
| TARIS Biomedical/ Allergan | Company acquisition | LiRIS for interstitial cystitis / bladder pain syndrome (IC/BPS) (phase II) | 587.5 |
| Santaris/ Roche (pRED) | Company acquisition | Locked Nucleic Acid (LNA) platform for RNA-targeting therapeutics | 450 |
| Sapiens Steering Brain Stimulation/ Medtronic | Company acquisition | Deep brain stimulation technologies for neurodegenerative diseases e.g. PD and essential tremor | 200 |
| Dream Pharma/ Alvogen | Company acquisition | Generics | 187 |
| Emergent BioSolutions/ Morphosys** | Licence, joint development & commercialisation | MOR209/ES414, anti-PSMA/anti-CD3 bi-specific antibody targeting prostate cancer (preclinical) | 183 |
| Immune Design/ Sanofi | Licence | GLAAS discovery platform to develop therapeutics for a selected food allergy | 168 |
| Guizhou Taibang Biological Products/ China Biologic | Company acquisition (19.84% stake) | Plasma-based products | 87.1+ |
| Ziopharm Oncology/ Solasia Pharma | Amendment of 2011 licence/ collaboration | Darinaparsin (Zinapar or ZIO-101) and related organoarsenic molecules | 72.2 |
| Millennium (Takeda)/ Infinity Pharma | Option to buy out future potential royalties | IPI-145 for treatment of blood cancers (phase III) | 57.5 |
| Rush University Medical Center/ DRI Capital | Acquisition of royalty rights | Ampyra (dalfampridine) extended release tablets (marketed) | 42 |
| Alpine Biosciences/ Oncothyreon | Company acquisition | Protocells, nanoparticle technology for targeted delivery of nucleic acids, proteins, peptides, small molecules (platform) | 27 |
| Valeo Pharma/ Valeant | Product portfolio acquisition | Dermatology brands and specialty products | 25.3 |
| ViaCyte/ Janssen R&D | Rights agreement | VC-01 based on pancreatic progenitor cells to treat type 1 diabetes (preclinical) | 20 |
| Hanmi Pharm/ Luye Pharma† | Licence | Poziotinib, a pan-HER inhibitor for the treatment of cancer (phase II) | 20 |
| Abbott/ US Department of Defense | Collaboration | To develop portable blood tests to evaluate potential concussions or mild traumatic brain injuries (TBIs) | 19.5 |
All deals are worldwide unless otherwise noted.
* US
** ww excluding US and Canada
† China
Subscribe to our email news alerts
- Top 10 benefits of virtual advisory boards: Save Time and Resources
- NIHR launches new framework to highlight health progress outcomes
- Johns Hopkins and National Cancer Unit develop new genetic risk-scoring method for major diseases
- UKHSA secures UK-based vaccine deal for future influenza pandemics
- Novo Nordisk and Valo Health agree deal worth up to $3.3bn to develop cardiovascular treatments
- Landscape review reveals £1.1bn of UK funding for rare diseases
No results were found
PMHub
Fishawack Health
Established in 2001, Fishawack Health (FH) is a purposefully built commercialization partner for the biopharmaceutical, medical technology, and wellness industries....
